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Abstract 
Background: Ribavirin, a nucleoside analogue, is administered in combination with 
interferon to patients with chronic hepatitis C. To evaluate the feasibility of ribavirin 
therapeutic drug monitoring, we investigated the influence of blood collection and pre-
analytical conditions on ribavirin concentrations and compared the results obtained from 
inter-laboratory blind tests by three laboratories using different analytical techniques.  
Material and Methods: On three occasions, blank serum samples spiked with ribavirin and 
pooled serum samples from patients on ribavirin were sent to the three laboratories. Two 
analytical techniques were based on LC-MS/MS and one on HPLC-UV, with protein 
precipitation or solid-phase extraction, all validated according to international guidelines.  
Results: Inter-batch and intra-batch mean relative errors ranged from –7.4 to +10.3 % and 
from –10.3 to +7.4%, respectively. Relative standard deviations were <13.5% and <10.6%, 
respectively. Linearity, assessed blindly, between 125 and 4550 ng/mL was excellent (r 
>0.991) for all three methods. The two LC-MS/MS techniques were slightly less precise and 
accurate than HPLC-UV, perhaps because the internal standard used was not a ribavirin 
isotope.  
Conclusion: Accurate and precise LC-MS/MS and HPLC-UV methods developed in three 
different laboratories provided excellent and consistent results to blind tests for ribavirin 
determination in spiked serum samples and pools of serum samples from patients with chronic 
HCV.  
 
Key-words: Hepatitis C, ribavirin, HPLC, LC-MS/MS, proficiency testing, therapeutic drug 
monioring. 
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Abbreviations: UV, ultraviolet; LC, liquid chromatography; HPLC, high-performance liquid 
chromatography; GTP, guanosine triphosphate; TDM, Therapeutic Drug Monitoring. 
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1. Introduction 
 
The combination of peginterferon and ribavirin [1,2] is the standard approved treatment of 
patients with chronic hepatitis C virus (HCV). Half of the patients with this combined therapy 
relapse or remain virological non responders. The main predictive factors of a poor sustained 
virological response (SVR) are an HCV genotype other than 2 or 3, a high baseline viral load 
and a dose of ribavirin <10.6 mg/kg of body weight (BW) [1]. Indeed, two clinical trials [1,2] 
suggested that ribavirin dose adjustment for BW may be beneficial, while two other studies in 
patients with chronic HCV receiving combination therapy [3,4] found no correlation between 
ribavirin dose adjusted for BW and a single ribavirin serum concentration time point at week 
4 (W4) or at steady state (W12), i.e. there was a poor dose-concentration relationship. A better 
concentration-effect than dose-effect relationship was reported by several groups [4-6].  In a 
recent cohort study [5], patients’ global exposure to ribavirin was widely distributed, despite 
dose-adjustment for BW.  
Ribavirin has a large distribution volume, a long half-life and large inter-individual 
pharmacokinetic variability [7]. Following a single oral dose, the plasma concentration of 
ribavirin exhibits a three-phase profile: rapid absorption, with a mean time to the maximum 
concentration (tmax) of about 1.5 h; rapid distribution (half life of approximately 3.7 h); and a 
long terminal elimination, the last measurable concentration time point being at 
approximately 100 h post-dose [7,8]. Recently, it has been suggested that the gastro-intestinal 
tract is the major site of ribavirin first-pass elimination [8]. High fat meals can increase 
ribavirin bioavailability by 46% relative to the fasting state [9], suggesting low oral 
bioavailability. Metabolism accounts for most of ribavirin elimination, but the exact 
mechanisms and sites involved are unknown. Glue et al [10] showed that hepatic dysfunction 
had no substantial influence on the apparent clearance of ribavirin, which would mainly be 
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affected by BW, gender, age and serum creatinine, although these four covariates only 
explained 27 to 40% of its inter-individual variability [3,11]. 
The first attempts at ribavirin pharmacokinetic (PK)-pharmacodynamic (PD) studies were 
based on single point sampling strategies. Jen et al reported that low ribavirin serum 
concentrations (with no precision on timing) at “steady state” (W4) were associated with a 
low SVR rate, but were less influential than the genotype or viral load [6]. Larrat et al also 
found an association between SVR and a single serum concentration taken 2-4 h after the 
morning dose of ribavirin at W12 (n=24; p=0.03) and W24 [4]. Taking into account ribavirin 
concentration-time profiles, a recent study in 24 patients with genotype 1 HCV showed that 
after the first ribavirin dose (D0), patients with SVR had a significantly higher AUC
0-12h
 
(p=0.03) and AUC
0-4h
 (p=0.03) than non-responders, with an AUC
0-4h
 threshold of 1755 
µg.h/L. Also, ribavirin may cause anemia in a dose-dependent manner. Therefore, monitoring 
ribavirin plasma concentrations could be useful for tailoring individual dosing of ribavirin. 
Several analytical methods have been developed for the determination of ribavirin in 
biological fluids (for review see [12]) including radioimmunoassays, capillary electrophoresis, 
or liquid chromatography coupled with UV [13, 14] or tandem mass-spectrometric detection 
[15, 16]. The reported sample preparation procedures were either based on protein 
precipitation with various solvents [12] or on solid-phase extraction [4-5, 13, 14]. However, 
these techniques were not compared head-to-head and, in the absence of an inter-laboratory 
blind test, their applicability to routine therapeutic drug monitoring (TDM) of ribavirin is 
unknown.  
The aim of the present study was to evaluate the feasibility of ribavirin TDM by comparing 
the results obtained at repeated inter-laboratory blind tests by three laboratories employing 
different HPLC methods, never compared or harmonized before (two with MS/MS and one 
with UV detection). 
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2. Materials and methods 
a. Description of the analytical methods 
The organic solvents, reagents, all of analytical grade, and the pure compounds were supplied 
by different retailers (Sigma Aldrich, Saint-Quentin Fallavier, France; Merck, Darmstadt, 
Germany; Prolabo, Fontenay-sous-Bois, France; Carlo Erba, Val-de-Reuil, France). The 
analytical methods applied by the three participating laboratories are described in Table 1. 
Briefly, serum or plasma samples were extracted using either solid-phase extraction with 100 
mg, 1 mL Bond-Elut Phenyl Boronic Acid cartridges (Varian, Harbor City, CA, USA), or a 
simple protein precipitation procedure. The LC-MS/MS methods were carried out with a 2000 
QTRAP
TM
 and a 3200 QTRAP
TM
 LC-MS/MS system, respectively (Applied-
Biosystem/Sciex, Foster City, CA, USA), equipped with a TurboIon-Spray
TM
 and a Turbo 
V
TM
 ionization source, respectively. HPLC-UV employed a UV 6000LP detector (Thermo 
Fisher Scientific, Les Ulis, France) operated at 214 and 240 nm. 
The three methods were validated in-house in terms of linearity, inter- and intra-assay 
precision and accuracy, and extraction recovery. Linearity was evaluated using least-square 
quadratic regression of ribavirin-to-internal standard (IS) peak-area ratios versus theoretical 
concentrations for the laboratories using MS/MS detection, and linear regression for HPLC-
UV. Accuracy was expressed as the bias relative to the theoretical concentrations, and 
precision as the percent root mean square error (RMSE%) of back-calculated concentrations. 
Intra-assay precision and accuracy were assessed at different concentration levels by 
extraction and analysis on the same day of replicates of fortified serum samples. 
Extraction recoveries were determined at several concentration levels, by spiking a series of 
ribavirin-free serum samples with the appropriate amounts of ribavirin and the internal 
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standard (IS), and another series with the IS alone. After extraction and evaporation, the dry 
extracts were reconstituted with the chromatographic mobile phase for samples of the first 
series, and with the mobile phase spiked with the nominal amount of ribavirin for samples of 
the second series. 
For the LC-MS/MS methods, ion suppression was investigated by injecting 10 different blank 
human serum samples into the LC system while a solution of ribavirin was continuously 
infused in parallel in the ionization source through a PEEK tee. 
b. Inter-laboratory blind tests 
The inter-laboratory survey carried out at the university hospitals of Grenoble, Limoges and 
Lyon, France (referenced here as Laboratories 1, 2 and 3 in a different order), involved blank 
serum samples spiked with ribavirin at known concentrations (blinded to the three 
laboratories) and pools of patients’ serum. Blood from patients treated with ribavirin was 
repeatedly collected into tubes without an anticoagulant at day 1, week 12, week 12 + 1 day 
and week 24 of ribavirin treatment, as part of a pharmacokinetic study [5]. All patients gave 
their written informed consent for this study, which was approved by the regional ethics 
committee and authorized by the French Drug Agency (AFSSAPS).  
After 15 minutes of centrifugation of blood samples at 1733 g and 4°C, serum was aliquoted 
and stored at -80°C in brown 1.5 mL polypropylene tubes until analysis. For this study, pools 
of serum were prepared by mixing 4 aliquots from 4 different patients sampled at the same 
time post-dose and treatment period. After vortex-mixing, these pools were aliquoted into 
brown 1.5 mL polypropylene tubes.  
Outdated drug-free serum from healthy-volunteers provided by the Etablissement Français du 
Sang was aliquoted and spiked with working solutions of ribavirin in water at different 
concentrations between 125 and 4550 ng/mL. 
All the samples were kept at –80°C until their shipment to the laboratories in dry ice. 
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Shipment 1 included 22 randomly distributed blank serum samples spiked at 10 different 
concentrations of ribavirin (125, 375, 775, 1400, 1750, 2150, 2650, 3150, 3750 and 4550 
ng/mL), including 5 replicates of the samples at 775, 1750 and 3150 ng/mL for estimating the 
intra-assay precision and accuracy. 
Shipment 2 was made of aliquots of the 3 spiked blank serum samples at 375, 2150 and 3750 
ng/mL already distributed in shipment 1, and 20 samples from patients’ serum pools. 
Shipment 3 contained aliquots of the same 3 spiked serum samples at 375, 2150 and 3750 
ng/mL (for inter-assay accuracy and precision estimation), and 20 aliquots of patients’ serum 
pools. 
3. Results 
The main method validation results obtained by each laboratory in-house are reported in 
Table 1. Intra- and inter-assay accuracy and precision were all <15.0% over the calibration 
ranges used. The lower band of these ranges (which was not the actual LOQ for at least one of 
the LC-MS/MS methods) was between 10 ng/mL and 100 ng/mL, depending on the intended 
use, whether TDM at steady-state, or pharmacokinetic studies after a single, or the first dose. 
Examples of chromatograms obtained in each laboratory are presented in Figure 1. The results 
of the ion suppression study performed by laboratories 1 and 2, using MS/MS detection, are 
shown in Figure 2. For method 1, a slight decrease of the signal close to 14 min led to an 
increase in the chromatographic run time up to 18 min (though the retention time of ribavirin 
and IS were around 4 min) to eliminate all contaminations. For method 2, the signal remained 
stable during ribavirin and internal standard elution (between 1.5 and 2.1 min), then slightly 
decreased around 4 min but returned to initial conditions before the 6
th
 minute.  
As part of the inter-laboratory survey, the intra-assay precision and accuracy were assessed 
blindly at three concentrations (775, 1750 and 3150 ng/mL), showing mean relative errors 
between –10.3 and +7.4% and RSD% always <10.6% (Figure 3). Similarly, inter-assay 
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precision and accuracy were evaluated using three other blank serum samples spiked at 375, 
2150 and 3750 ng/mL, repeatedly sent with shipments 1, 2 and 3. The mean relative error 
ranged between –7.4 and +10.3% and the RSD% was <13.5% (Figure 4). The linearity of the 
three analytical methods was assessed from the results reported for the blank serum samples 
spiked at 10 different concentrations between 125 and 4550 ng/mL (Figure 5). The calculated 
coefficients of correlation were all >0.991, with the best correlation being obtained by the 
laboratory using HPLC-UV (lab 2). The mean relative error (MRE) of back-calculated 
concentrations varied between –10.0 and +16.0% with the highest MRE for the lowest spiked 
concentrations, and the inter-laboratory RSD ranged from 0.3 to 14.6%.  
The applicability of the three methods was also investigated through the analysis of pools of 
samples collected from patients with hepatitis C at day 0, week 12 and week 24 after the 
beginning of the treatment with ribavirin. Each pool corresponded to a given sampling time, 
between 0.5 hour and 10 hours post-dose, resulting in a large range of concentrations. Among 
the 40 pools analyzed, in only three instances was inter-laboratory RSD >30%, due to outlier 
results reported by any one of the laboratories with regards to the two others. For all the other 
patients’ pools, the reported concentrations varied from 157 to 3572 ng/mL, the inter-
laboratory RSD% was 8.7% on average and always < 17.0% (Figure 6). 
 
4. Discussion 
This study shows that HPLC-UV or LC-MS/MS methods developed in three different 
laboratories and employing different types of sample extraction procedures gave excellent and 
equivalent results for ribavirin determination in blinded tests. The data were from both spiked 
and patients’ serum samples, suggesting that routine ribavirin monitoring is technically 
feasible, despite the absence of commercial assays.  
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The three analytical techniques presented were set up for different clinical trials, with the aim 
of measuring either ribavirin morning trough concentrations at steady-state (labs 2 and 3) or 
ribavirin pharmacokinetic profiles after the first and repeated doses (lab 1), which explains the 
differences in terms of LOQ and linearity range, in particular between the two LC-MS/MS 
techniques. All three fulfilled the international requirements for analytical method validation. 
The previously published sample preparation procedures were either based on protein 
precipitation with various solvents [12] or solid-phase extraction with cartridges containing 
phenyl boronic acids with a high affinity for compounds containing diol moieties, due to 
reversible boronate formation [4-5, 11-14]. Recently, Morello et al. [14] have used another 
type of extraction cartridge (Microsep 3K Omega) and liquid chromatography with UV 
detection, yielding similar results. As recently reviewed [12], other LC-MS/MS methods for 
ribavirin determination have been published [15-17], some of which yielded shorter turn-
around times. However, the absence of the ion suppression phenomenon, frequently observed 
when protein precipitation procedures are employed, was not documented in these papers. 
Different analytical approaches have been employed here to minimize this phenomenon, i.e., 
in method 2, dilution of the sample before precipitation and in method 1 solid-phase 
extraction, which is theoretically cleaner and tends to prevent or minimize ion suppression. 
However, according to the results presented in figure 2, this phenomenon could not be totally 
avoided, though no ion suppression was visible at the retention times of ribavirin and the 
internal standards. The use of an isotope-labelled analog of ribavirin as internal standard 
could help to compensate for any residual ion suppression and, above all, improve precision. 
UV detection was the most frequently employed technology for ribavirin, owing to the 
accessible analytical ranges involved [4, 11, 13, 14, 18-21], but the sample volumes required 
were generally higher and the extraction procedure longer than those for most of the LC-
MS/MS methods.  
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The results obtained from the inter-laboratory blind tests in the present study were excellent 
for all three methods, and even better in terms of precision and linearity for the HPLC-UV 
technique, although the in-house method validation results were almost equivalent (Table 1). 
LC-MS/MS is used increasingly for TDM [22] in clinical laboratories. However, its 
variability can be somewhat higher than that of “classical” HPLC in the absence of isotope-
labelled internal standards, and LC-MS/MS techniques need to be thoroughly validated, 
including the investigation of ion suppression or potential interferences, before they can be 
applied in a clinical setting [23]. Otherwise, quantification or even identification errors can 
occur, and the advantages of mass-spectrometry can be lost. 
The recently reported relationship between early exposure to ribavirin (plasma AUC
0-4h
) and 
clinical outcome in hepatitis C patients, [5] together with the results of the present study, 
suggest that HPLC-UV or LC-MS/MS techniques can be used for the routine TDM of 
ribavirin as well as to conduct prospective multicentre clinical trials to validate the clinical 
benefit of such monitoring. The setting up of a larger and regular inter-laboratory proficiency 
testing scheme, involving more laboratories, using different detection modes, would be of the 
utmost interest in both these aims. 
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Table 1: Description of the three analytical methods developed for the analysis of ribavirin 
 
 Method 1 Method 2 Method 3 
Volume sample  200 µL 5 µL 500 µL 
Extraction 
procedure 
• Addition of 700 µL of an ammonium acetate 
solution at pH 8.5 and 50 µL of a 10 mg/L 
solution of 6-methylaminopurine 9-
ribofuranoside (IS) in water. 
• Solid-phase extraction on a PBA cartridge 
equilibrated with methanol–formic acid (97:3 
by volume) and 0.25M ammonium acetate. 
• Elution with 3 mL of methanol–formic acid 
(97:3 by volume). 
• Dilution with 15 µL of water. 
• Addition of 200 µL of a 1 µg/L 
solution of 3-methyl cytidine 
methosulfate (IS) in acetonitrile-water-
perchloric acid (97:2:1 by volume). 
• Vortex-mixing of the mixture for 30 
seconds and centrifugation at 20,000 g 
for 10 minutes. 
. 
• Addition of 500 µL of an ammonium 
acetate solution at pH 9 and 30 µL of a 
100 mg/L solution of 3-methyl cytidine 
methosulfate (IS) in water. 
• Equilibration of the PBA cartridge 
with methanol–formic acid (97:3 by 
volume) and 0.25 M ammonium acetate 
at pH 9. 
• Elution with 3 mL of methanol–
formic acid (97:3 by volume). 
 
Column 
Atlantis HILIC Silica, 5 µm (150 × 2.1 mm) 
(Waters) 
Luna HILIC, 3 µm (100 × 2.0 mm) 
(Phenomenex) 
Uptisphere HDO-QS, 3 µm (150 × 
4.6mm) (Interchim) 
Mobile phase Aqueous ammonium formate and acetonitrile 
Aqueous ammonium acetate and 
acetonitrile 
Aqueous orthophosphoric acid and 
acetonitrile 
Detection mode 
MS/MS, ESI, positive ionization mode. 
Ribavirin (ammonium adduct): m/z 262.1/113.2 
(quantification); m/z 262.1/96.2, m/z 
245.1/113.2 (confirmation); 
IS: m/z 282.2/150.1. 
MS/MS, ESI, positive ionization mode. 
Ribavirin: m/z 245.2/113.1 
(quantification) ; m/z 245.2/96.2 
(confirmation); IS, m/z 258.1/126.1. 
UV detection at 214 and 240 nm. 
Analytical range 10-5000 ng/mL 100-7000 ng/mL 100-10000 ng/mL 
Validation results 
Intra-assay accuracy (n=5): 
CV < 7.8 %, MRE < 6.5% 
Inter-assay accuracy (n=5): 
CV < 13.3 %, MRE < 5.7 % 
Recovery (n=3): > 92.8 % 
Intra-assay accuracy (n=6): 
CV < 3.9 %, MRE < 3.1 % 
Inter-assay accuracy (n= 6): 
CV < 10.7 %, MRE < 6.7 % 
Recovery (n=3): > 92.9% 
Intra-assay accuracy (n=6): 
CV <6.7 %, MRE <7.5 % 
Inter-assay accuracy (n=23): 
CV < 6.0 %, MRE < 1.8 % 
Recovery (n= 5):> 55.3 % 
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Figure legends 
 
Figure 1: Typical chromatograms of extracted patients’ samples analysed with method 1 (A), 
method 2 (B) and method 3 (C). 
 
Figure 2: Investigation of the ion suppression phenomenon by means of a continuous infusion of 
ribavirin at 1 µg/mL and parallel injection of extracts of blank samples applying method 1 (A) and 
method 2 (B). 
 
Figure 3: Intra-series precision and accuracy: relative bias obtained by the three laboratories at 
775 ng/mL (A), 1750 ng/mL (B) and 3150 ng/mL (C). 
 
Figure 4: Inter-series precision and accuracy: relative bias obtained by the three laboratories at 
375, 2150 and 3750 ng/mL. 
 
Figure 5: Blind linearity evaluation of the three methods. 
 
Figure 6: Analysis of pools of patients’ samples: relative differences of ribavirin 
concentrations found by each laboratory with respect to the mean measured values. 
 
 
 
